Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00546897 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00546897 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 48 participants.
The verdict
NCT00546897, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study is designed to test the safety and efficacy of lenalidomide in older patients (age \> 60 years) with untreated acute myeloid leukemia without chromosomal abnormalities involving 5q.
Interventions
- DRUG Lenalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2007-02 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00546897
The ClinicalTrials.gov registry entry for NCT00546897 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide is the first listed.
NCT00546897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00546897 about?
NCT00546897 is a clinical study titled "Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities". This study is designed to test the safety and efficacy of lenalidomide in older patients (age \> 60 years) with untreated acute myeloid leukemia without chromosomal abnormalities involving 5q.
What is the current status of trial NCT00546897?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2007-02. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00546897?
The interventions under investigation include: Lenalidomide (DRUG).
Who is sponsoring clinical trial NCT00546897?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.